News & Events about Iovance Biotherapeutics Inc.
Iovance Biotherapeutics (NASDAQ: IOVA) shares are trading higher on Monday after the company completed its Biologics License Application submission for lifileucel.
read more...
Globe Newswire
3 months ago
SAN CARLOS, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following conferences: H.C. Wainwright Cell ...
Ticker Report
4 months ago
Iovance Biotherapeutics (NASDAQ:IOVA Get Rating) had its price target hoisted by analysts at Truist Financial from $16.00 to $17.00 in a report issued on Tuesday, The Fly reports. The firm currently has a buy rating on the biotechnology companys stock. Truist Financial&#...
Globe Newswire
4 months ago
23 January 2023 Clinigen divests Proleukin to Iovance Biotherapeutics for 166.7 million The deal includes a 41.7 million milestone payment and double-digit Proleukin global sales royalties Clinigen Limited (Clinigen) (the Company), the global pharmaceutical services company, has entered into an ...
Globe Newswire
4 months ago
Acquisition of Worldwide Rights to Proleukin Provides Immediate and Ongoing Revenue and Secures IL-2 Supply for Clinical and Future Commercial TIL Therapy Positive FDA Feedback on Phase 3 Confirmatory Study in Frontline Advanced (Metastatic or Unresectable) Melanoma Positive Clinical Data in Anti-PD...